Vol. I · No. 33
Thursday, August 13, 2026
Issue: Summer · 2026
Established · MMXXVI
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com
Geroevidence · Editorial desk · Intervention Profiles

Intervention Profiles

Deep dives into individual longevity compounds — mechanism, evidence, trials.

27 articles in this category · ← All categories
§ Intervention Profiles · 27 articles · page 2 of 2
Metformin for longevity: the full evidence profile in 2026
The most-prescribed diabetes drug in history has a compelling longevity hypothesis and some of the strongest observational evidence in the field. Here is the complete evidence picture ahead of TAME results.
July 19, 2026  ·  14 min read
NMN for longevity: the complete evidence profile in 2026
NMN raises NAD+ levels in humans — that much is established. Whether raising NAD+ translates to longevity benefit in healthy adults is the question the current evidence cannot yet answer.
July 19, 2026  ·  13 min read
NR (nicotinamide riboside) for longevity: the complete evidence profile in 2026
NR was the first oral NAD+ precursor to be tested in human RCTs. Here is what those trials showed, how the evidence compares to NMN, and what remains unknown.
July 19, 2026  ·  12 min read
GLP-1 agonists and cardiovascular mortality: a deep dive into the outcome trial data
The SELECT, LEADER, and SUSTAIN-6 trials established GLP-1 agonists as cardiovascular medicines. Here is what that evidence means for longevity medicine specifically.
July 19, 2026  ·  13 min read
Low-dose lithium and longevity: epidemiology, mechanism, and the evidence gap
Epidemiological studies link lithium in drinking water to lower dementia rates and longer lifespan. The human supplementation evidence is sparse — here is what the data shows.
July 19, 2026  ·  10 min read
Spermidine and autophagy: what the human evidence actually shows
A naturally occurring polyamine, studied for the same autophagy pathway that gives rapamycin its mechanistic case — with a much earlier-stage human evidence base.
June 24, 2026  ·  8 min read
Acarbose for longevity: the ITP mouse data and human diabetes evidence
A decades-old diabetes drug extends lifespan in a rigorous mouse program — but its human longevity evidence tells a different, more limited story.
June 24, 2026  ·  9 min read
17α-Estradiol: a lifespan effect with a sex-specific puzzle
A non-feminizing estrogen extends lifespan in male mice in NIA-backed data — and shows no comparable effect in females. What the evidence shows, and what remains unexplained.
June 23, 2026  ·  10 min read
Taurine and longevity: what the evidence actually shows
A 2023 mouse study reignited interest in an amino acid most people associate with energy drinks. Here is what the data shows, what it doesn't, and why Geroevidence hasn't assigned it an evidence tier yet.
June 23, 2026  ·  9 min read
Rapamycin for longevity: what the clinical evidence actually shows in 2026
A structured synthesis of every published human trial and major animal study — evidence strength rated honestly, with what is known, what is unknown, and what trials are ongoing.
May 13, 2026  ·  14 min read
GLP-1 agonists beyond weight loss: the cardiovascular and longevity evidence
Semaglutide and tirzepatide are the most prescribed drugs in medicine. The weight loss story is well known. The cardiovascular and longevity evidence is more important and less understood.
May 13, 2026  ·  12 min read
SGLT2 inhibitors and aging: what the evidence actually shows
Empagliflozin and dapagliflozin have some of the strongest cardiovascular and renal outcomes data in medicine. Their longevity relevance is underappreciated. Here is the evidence.
May 13, 2026  ·  10 min read
← Newer
Page 2 of 2